Arts J, Herr I, Lansink M, Angel P and Kooistra T (1997). Cell-type specific DNA-protein interactions at the tissue-type plasminogen activator promoter in human endothelial and HeLa cells in vivo and in vitro. Nucl. Acid Res. 25, 311-317.
Boehler T, Herr I and Debatin K-M. (1997). Downregulation of increased CD95 (APO-1/Fas) Ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy. Blood 90, 886-887.
Los M, Herr I, Fulda S, Friesen C, Schulze-Osthoff K and Debatin K-M (1997). Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood, 90, 3118-3129.
Fulda S, Sieverts H, Friesen C, Herr I and Debatin K-M (1997). The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res. 57, 3823-3829.
Herr I, Wilhelm D, Boehler T, Angel P and Debatin K-M (1997). Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBOJ. 16, 6200-6208.
Boehler T, Baeumler C, Herr I, Groll A, Kurz M and Debatin K-M (1997). Activation of the CD95-system increases with disease progression in human immunodeficiency virus type 1-infected children and adolescents. Pediatr. Infect. Dis. J. 16, 754-759.
Herr I, Balemans L, Boehler T, Walczak H and Debatin K-M (1996). Monitoring of CD95 (APO-1/Fas) ligand expression in human T cells by quantitative RT-PCR. Cell Death and Differentiation 3, 299-305.
Baeumler C B, Boehler T, Herr I, Benner A, Krammer P H and Debatin K-M (1996). Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1-infected children. Blood 88, 1741-1746.
Ehret A, Westendorp M O, Herr I, Debatin K-M, Heeney J L, Frank R and Krammer P H (1996). Resistance of chimpanzee T cells to human immunodeficiency virus type 1 Tat-enhanced oxidative stress and apoptosis. J. Virol. 70, 6502-6507.
Friesen C*, Herr I* (*equal contribution), Krammer P and Debatin K-M (1996). Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis of leukemia cells. Nature Medicine 2, 574 - 577.
Bauknecht T, Jundt F, Herr I, Oehler T, Delius H, Shi Y, Angel P and Zur Hausen H (1995). A "switch region" determines cell type specific positive or negative action of YY1 on the activity of the HPV-18 promoter. J. Virol. 69, 1-12.
Jundt F, Herr I, Angel P, Zur Hausen H and Bauknecht T (1995). Transcriptional control of human papillomavirus type 18 oncogene expression in different cell lines: role of transcription factor YY1. Virus-Genes 11, 53-8.
Schorpp M, Mattei M-G, Herr I, Gack S, Schaper J and Angel P (1995). Structural organization and chromosomal localization of the mouse collagenase type I gene. Biochem. J. 308, 211-217.
van Dam H, Wilhelm D, Herr I, Steffen A, Herrlich P and Angel P (1995). ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction on response to genotoxic agents. EMBO J. 14, 1798-1811.
Herr I, van Dam H and Angel P (1994). Binding of promoter-associated AP-1 is not altered during induction and subsequent repression of the c-jun promoter by TPA and UV irradiation. Carcinogenesis 15, 1105-1113.
Hagmeyer B M, Koenig H, Herr I, Offringa R, Zantema A, van der Eb A J, Herrlich P and Angel P (1993). Adenovirus E1A negatively and positively modulates transcription of AP-1 dependent genes by dimer-specific regulation of the DNA binding and transactivation activities of Jun. EMBO J. 12, 3559-3572.